APOE, variants, traits, and what the research shows

Plain-English summary of the APOE gene: 101 high-magnitude variants on file, 1 with published research summaries. Variants linked to rare_disease, kidney, cardiovascular.

High-magnitude variants on file
101
With published research summary
1
Trait themes
3

Traits this gene affects

  • rare_disease
  • kidney
  • cardiovascular

Top variants in APOE

Highest-impact rsids on file, sorted by magnitude. Linked entries have a full research summary; unlinked entries are in the catalog but not yet written up.

rsidMagnitudePrimary trait
rs1219183925.5rare_disease
rs1219183945.5rare_disease
rs1219183955.5rare_disease
rs1219183975.5kidney
rs1219183985.5rare_disease
rs1408089095.5cardiovascular
rs1443540135.5cardiovascular
rs1908530815.5cardiovascular
rs2016720115.5kidney
rs21221327185.5rare_disease
rs289315785.5rare_disease
rs289315795.5cardiovascular
rs3975142535.5rare_disease
rs3975142545.5rare_disease
rs5157261485.5cardiovascular
rs5635716895.5neurological
rs1219183935.0metabolic
rs1219183965.0rare_disease
rs1219183995.0cardiovascular
rs13325910685.0kidney

How your prescriber uses this gene

4 drug labels reference this gene. 3 require pharmacogenomic testing before prescription; another 0 are marked actionable.

Every entry below comes from a national regulator (FDA, EMA, HCSC, PMDA, or Swissmedic) via PharmGKB. Talk to a prescriber before acting on any pharmacogenomic result.

Testing required 3

Regulators require pharmacogenomic testing before prescription.

  • aducanumab FDA
  • donanemab EMA · FDA alt drug suggested
  • lecanemab FDA
1 more drug labeled but not marked actionable

Not classified 1

Testing level not specified on this label.

  • pravastatin FDA